Industrial bioscience company Amyris has appointed Kathleen Valiasek, a senior finance and business executive with over 20 years’ experience serving start-up, venture-backed and Fortune 500 companies as chief financial officer. She replaces Raffi Asadorian, who has resigned to pursue a new opportunity, but will continue to support specific projects, as well as serve in an ad hoc consulting capacity to ensure a smooth transition.

Ms. Valiasek’s experience encompasses serving with fast-growing companies including those among the Fortune 500 and across the life sciences, tech, retail, telecommunications, real estate, and healthcare sectors. Prior to joining Amyris, Ms. Valiasek was founder and chief executive officer of Lenox Group, a finance and strategic consulting firm.

“Following completing a record year of revenue growth, we are entering 2017 with the partnerships and product demand to further grow the business and improve shareholder value,” said John Melo, president and chief executive officer, Amyris. “Kathy’s strong financial management and business experience at a time of such rapid growth and significant commercial expansion will be a key asset in continuing to build on Amyris’s momentum.”